Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

224 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

16 enrolled

Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT00372515 2018-01-31

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Phase 1 Completed

7 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Head & Neck

Salivary Gland Neoplasms

NCT00452244 2017-08-25

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

110 enrolled

Thoracic

Lung Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00310154 2017-05-30

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1 Completed

45 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03157310 2017-05-17

Bone Metastasis on the Survival of Gefitinib Effective Patients

Phase NA Completed

265 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00186979 2017-04-26

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 1 Completed

34 enrolled

Other solid neoplasm

Solid Tumors

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

35 enrolled

Thoracic

Lung Neoplasms

NCT00231465 2017-03-03

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT01024413 2017-03-01

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Phase 3 Completed

256 enrolled

Thoracic

Lung Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01404260 2017-01-27

ISCAN

Phase 3 Completed

219 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

FLAURA

BM

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

GOAL

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

BKM120

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

MK-3475-021

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

PROGRESS

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

LADIE

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

IMPRESS

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Third-line Treatment of Gefitinib in NSCLC Patients

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

MetAction

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

CGMT

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Iressa Study in Patients With Salivary Gland Cancer

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Bone Metastasis on the Survival of Gefitinib Effective Patients

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

ISCAN